Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

BACKGROUND: Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. CASE: We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experie...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Chanhee, Bellone, Stefania, Schwartz, Peter E., Govindan, Serengulam V., Sharkey, Robert M., Goldenberg, David M., Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030029/
https://www.ncbi.nlm.nih.gov/pubmed/29977989
http://dx.doi.org/10.1016/j.gore.2018.05.009
Descripción
Sumario:BACKGROUND: Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. CASE: We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events. CONCLUSION: Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.

Ejemplares similares